Abstract |
When the 'handle region' of the prorenin prosegment interacts with the ( pro)renin receptor, the prorenin molecule partially changes the conformation to an enzymatically active state. On the other hand, the receptor triggers its own intracellular signalling pathways independent of the renin-angiotensin system (RAS). The 'handle region' peptide competitively binds to the receptor as a decoy peptide and inhibits both the non-proteolytic activation of prorenin and the RAS-independent intracellular signals. Therefore, prorenin receptor blockers including the decoy peptide may have superior benefits on end-organ damage in diabetes and hypertension compared with conventional RAS inhibitors.
|
Authors | Atsuhiro Ichihara, Yuki Kaneshiro, Fumiaki Suzuki |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 15
Issue 10
Pg. 1137-9
(Oct 2006)
ISSN: 1744-7658 [Electronic] England |
PMID | 16989590
(Publication Type: Editorial, Review)
|
Chemical References |
- Drugs, Investigational
- Receptors, Cell Surface
- Renin
- Prorenin Receptor
|
Topics |
- Animals
- Cardiovascular Diseases
(complications, drug therapy, metabolism)
- Diabetes Mellitus
(drug therapy, etiology, metabolism)
- Drugs, Investigational
(pharmacology, therapeutic use)
- Humans
- Hypertension
(drug therapy, etiology, metabolism)
- Receptors, Cell Surface
(antagonists & inhibitors, physiology)
- Renin
(metabolism, physiology)
- Prorenin Receptor
|